Stallergenes Greer plc Annual Financial Report
16 Aprile 2018 - 8:00AM
UK Regulatory
TIDM0RB9
This press release features multimedia. View the full release
here: https://www.businesswire.com/news/home/20180415005016/en/
Stallergenes Greer Announces Publication of Its 2017 Annual
Report
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company
specializing in treatments for respiratory allergies, today
announced the publication of its 2017 Annual Report.
Approved by the Company's Board of Directors on 13 April 2018,
the report can be downloaded via the link below.
http://stallergenesgreer.com/sites/default/files/investors/documents/2017_annual_report.pdf
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global
healthcare company specializing in the diagnosis and treatment of
allergies through the development and commercialization of allergy
immunotherapy products and services. Stallergenes Greer plc is the
parent company of GREER Laboratories, Inc. (whose registered office
is in the US) and Stallergenes SAS (whose registered office is in
France).
TRADING INFORMATIONName: Stallergenes GreerISIN: GB00BZ21RF93 1
- Ticker: STAGRICB Classification: 4577LEI:
213800CYVZA7GJQEME86Market: Euronext Paris regulated market
Additional information is available at
http://www.stallergenesgreer.com.
This document (including information incorporated by reference
in this document), oral statements made and other information
published by the Company contain statements that are or may be
forward-looking with respect to the financial condition and/or
results of operations and businesses of the Company. These
statements can be identified by the use of forward-looking
terminology such as "believe," "expects," "project," "estimated,"
"forecast," "should," "plan," "may" or the negative of any of
these, or other variations thereof, or comparable terminology
indicating expectations or beliefs concerning future events. These
forward-looking statements include risk and uncertainty because
they relate to events and depend on circumstances that will occur
in the future. Without being exhaustive, such factors include
economic situations and business conditions, including legal and
product evaluation issues, fluctuations in currencies and demand,
and changes in competitive factors. These and other factors are
more fully described in the Company's 2016 annual report published
on 28 April 2017 on the Company's website
www.stallergenesgreer.com. Actual results may differ from those set
forth in the forward-looking statements, due to various factors.
Save as required by applicable law, neither the Company nor any
other person assumes any obligation to update these forward-looking
statements or to notify any person of any such update.
Communications and Investor RelationsNatacha GassenbachTel: +1
(617) 225 8013Email:
natacha.gassenbach@stallergenesgreer.comorCaitlin StefanikTel: +1
(857) 331 4117Email: caitlin.stefanik@stallergenesgreer.comorMedia
Relations AgencyHavas Worldwide Paris (Europe)Lucas Heral+33 6 77
01 47 49E-mail : lucas.heral@havas.comorInvestor Relations
AgencyFTI ConsultingArnaud de CheffontainesTel: +33 1 47 03 68
10Email: stalleregenesgreer@fticonsulting.com
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180415005016/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
April 16, 2018 02:00 ET (06:00 GMT)
Grafico Azioni Stallergenes Greer (LSE:0RB9)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Stallergenes Greer (LSE:0RB9)
Storico
Da Giu 2023 a Giu 2024